About Arcutis Biotherapeutics, Inc.
https://www.arcutis.comArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
CEO
Todd Franklin Watanabe
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 132
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Needham
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Mizuho
Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JENNISON ASSOCIATES LLC
Shares:12.25M
Value:$327.55M
RUBRIC CAPITAL MANAGEMENT LP
Shares:10.75M
Value:$287.33M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:10.48M
Value:$280.08M
Summary
Showing Top 3 of 255
About Arcutis Biotherapeutics, Inc.
https://www.arcutis.comArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $99.22M ▲ | $82.01M ▼ | $7.41M ▲ | 7.47% ▲ | $0.06 ▲ | $11.12M ▲ |
| Q2-2025 | $81.5M ▲ | $88.62M ▲ | $-15.89M ▲ | -19.49% ▲ | $-0.13 ▲ | $-11.95M ▲ |
| Q1-2025 | $65.85M ▼ | $81.55M ▲ | $-25.06M ▼ | -38.06% ▼ | $-0.2 ▼ | $-18.67M ▼ |
| Q4-2024 | $71.36M ▲ | $72.09M ▼ | $-10.79M ▲ | -15.12% ▲ | $-0.09 ▲ | $-4.46M ▲ |
| Q3-2024 | $44.76M | $78.32M | $-41.54M | -92.81% | $-0.33 | $-33.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $191.07M ▼ | $370.98M ▲ | $212.9M ▼ | $158.07M ▲ |
| Q2-2025 | $191.13M ▼ | $352.43M ▲ | $213.46M ▲ | $138.97M ▼ |
| Q1-2025 | $198.09M ▼ | $344.11M ▼ | $201.45M ▲ | $142.66M ▼ |
| Q4-2024 | $227.96M ▼ | $348.89M ▼ | $191.35M ▼ | $157.54M ▲ |
| Q3-2024 | $330.56M | $437.35M | $280.71M | $156.64M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $7.41M ▲ | $-1.75M ▼ | $-25.25M ▼ | $1.48M ▲ | $-25.62M ▼ | $-1.75M ▼ |
| Q2-2025 | $-15.89M ▲ | $324K ▲ | $17.42M ▲ | $1.38M ▲ | $19.33M ▲ | $246K ▲ |
| Q1-2025 | $-25.06M ▼ | $-30.38M ▼ | $11.75M ▼ | $395K ▲ | $-18.23M ▲ | $-30.99M ▼ |
| Q4-2024 | $-10.79M ▲ | $-748K ▲ | $34.88M ▼ | $-97.41M ▼ | $-63.52M ▼ | $-5.75M ▲ |
| Q3-2024 | $-41.54M | $-34.69M | $84.78M | $394K | $50.58M | $-34.83M |
Revenue by Products
| Product | Q3-2022 | Q4-2022 | Q3-2023 | Q4-2023 |
|---|---|---|---|---|
 Other Revenue | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
 Product | $0 ▲ | $0 ▲ | $10.00M ▲ | $20.00M ▲ |
CEO
Todd Franklin Watanabe
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 132
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Needham
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Mizuho
Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JENNISON ASSOCIATES LLC
Shares:12.25M
Value:$327.55M
RUBRIC CAPITAL MANAGEMENT LP
Shares:10.75M
Value:$287.33M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:10.48M
Value:$280.08M
Summary
Showing Top 3 of 255